|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000021762 |
Summary for OSBPL5 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000021762 | Gene symbol | OSBPL5 |
| Gene name | oxysterol binding protein like 5 | |
| HGNC | 16392 | |
| Entrez ID | 114879 | |
| Gene type | protein_coding | |
| Synonyms | OSBPL5|KIAA1534|ORP5|OBPH1 | |
| UniProtAcc | Q9H0X9 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for OSBPL5 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| OSBPL5 | 1.18e+03 | -1.33e+00 | 2.40e-01 | -5.56e+00 | 2.75e-08 | 3.18e-07 | BLCA |
| OSBPL5 | 8.04e+02 | 1.53e+00 | 3.87e-01 | 3.94e+00 | 8.22e-05 | 3.69e-04 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for OSBPL5 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for OSBPL5 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg26391219 | chr11:3167977 | CGI:chr11:3164901-3165538 | promoter | 6.08e-01 | 4.37e-01 | 3.49e+00 | 4.79e-04 | 5.88e-03 | 1.72e-01 |
| LIHC | cg06131936 | chr11:3166041 | CGI:chr11:3164901-3165538 | promoter,gene body | 4.58e-01 | 3.33e-01 | 4.26e+00 | 2.08e-05 | 2.02e-04 | 1.24e-01 |
| LIHC | cg03617572 | chr11:3166401 | CGI:chr11:3164901-3165538 | promoter,gene body | 6.91e-01 | 5.89e-01 | 4.39e+00 | 1.16e-05 | 1.24e-04 | 1.02e-01 |
| LIHC | cg12348511 | chr11:3166448 | CGI:chr11:3164901-3165538 | promoter,gene body | 5.92e-01 | 4.68e-01 | 4.62e+00 | 3.92e-06 | 4.82e-05 | 1.24e-01 |
| LIHC | cg22353828 | chr11:3166474 | CGI:chr11:3164901-3165538 | promoter,gene body | 5.29e-01 | 4.26e-01 | 4.18e+00 | 2.86e-05 | 2.64e-04 | 1.03e-01 |
| DLBC | cg03857384 | chr11:3166547 | CGI:chr11:3164901-3165538 | promoter,gene body | 8.29e-01 | 9.36e-01 | -2.32e+00 | 2.05e-02 | 3.55e-02 | -1.07e-01 |
| DLBC | cg18897335 | chr11:3166560 | CGI:chr11:3164901-3165538 | promoter,gene body | 7.14e-01 | 8.28e-01 | -2.67e+00 | 7.60e-03 | 1.87e-02 | -1.14e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUAD | cg03617572 | chr11:3166401 | CGI:chr11:3164901-3165538 | promoter,gene body | 7.63e-01 | 8.71e-01 | -4.01e+00 | 6.05e-05 | 1.85e-04 | -1.08e-01 |
| LUAD | cg22353828 | chr11:3166474 | CGI:chr11:3164901-3165538 | promoter,gene body | 6.07e-01 | 7.13e-01 | -3.53e+00 | 4.22e-04 | 9.40e-04 | -1.06e-01 |
| LUAD | cg09330834 | chr11:3166786 | CGI:chr11:3164901-3165538 | promoter | 7.34e-01 | 8.48e-01 | -4.29e+00 | 1.77e-05 | 6.72e-05 | -1.14e-01 |
| LUAD | cg26391219 | chr11:3167977 | CGI:chr11:3164901-3165538 | promoter | 5.09e-01 | 6.16e-01 | -3.76e+00 | 1.71e-04 | 4.41e-04 | -1.07e-01 |
| HNSC | cg24226590 | chr11:3165747 | CGI:chr11:3164901-3165538 | UTR,promoter,exon,gene body | 6.69e-01 | 7.95e-01 | -3.78e+00 | 1.55e-04 | 3.74e-04 | -1.26e-01 |
| LUSC | cg25487804 | chr11:3166281 | CGI:chr11:3164901-3165538 | promoter,gene body | 8.15e-01 | 9.49e-01 | -3.93e+00 | 8.55e-05 | 6.55e-04 | -1.34e-01 |
| LUSC | cg23910098 | chr11:3166304 | CGI:chr11:3164901-3165538 | promoter,gene body | 8.85e-01 | 9.89e-01 | -4.08e+00 | 4.43e-05 | 5.44e-04 | -1.05e-01 |
| LUSC | cg12491594 | chr11:3166296 | CGI:chr11:3164901-3165538 | promoter,gene body | 8.66e-01 | 9.89e-01 | -3.95e+00 | 7.75e-05 | 6.33e-04 | -1.23e-01 |
| LUSC | cg08453750 | chr11:3166352 | CGI:chr11:3164901-3165538 | promoter,gene body | 8.12e-01 | 9.14e-01 | -3.37e+00 | 7.45e-04 | 2.14e-03 | -1.02e-01 |
| LUSC | cg03857384 | chr11:3166547 | CGI:chr11:3164901-3165538 | promoter,gene body | 7.16e-01 | 9.84e-01 | -4.42e+00 | 9.74e-06 | 5.26e-04 | -2.69e-01 |
| LUSC | cg15718663 | chr11:3166554 | CGI:chr11:3164901-3165538 | promoter,gene body | 7.38e-01 | 9.64e-01 | -3.68e+00 | 2.34e-04 | 1.06e-03 | -2.25e-01 |
| LUSC | cg05982473 | chr11:3166573 | CGI:chr11:3164901-3165538 | promoter,gene body | 8.47e-01 | 9.89e-01 | -4.34e+00 | 1.41e-05 | 5.26e-04 | -1.42e-01 |
| LUSC | cg01309081 | chr11:3166132 | CGI:chr11:3164901-3165538 | promoter,gene body | 6.78e-01 | 7.91e-01 | -3.01e+00 | 2.65e-03 | 5.12e-03 | -1.13e-01 |
| LUSC | cg16712438 | chr11:3166167 | CGI:chr11:3164901-3165538 | promoter,gene body | 7.18e-01 | 8.42e-01 | -3.22e+00 | 1.30e-03 | 3.09e-03 | -1.24e-01 |
| LUSC | cg09729166 | chr11:3166359 | CGI:chr11:3164901-3165538 | promoter,gene body | 7.56e-01 | 8.84e-01 | -4.30e+00 | 1.70e-05 | 5.26e-04 | -1.28e-01 |
| LUSC | cg03617572 | chr11:3166401 | CGI:chr11:3164901-3165538 | promoter,gene body | 7.06e-01 | 8.86e-01 | -4.04e+00 | 5.31e-05 | 5.65e-04 | -1.80e-01 |
| LUSC | cg12348511 | chr11:3166448 | CGI:chr11:3164901-3165538 | promoter,gene body | 6.27e-01 | 8.18e-01 | -3.82e+00 | 1.33e-04 | 7.94e-04 | -1.91e-01 |
| LUSC | cg22353828 | chr11:3166474 | CGI:chr11:3164901-3165538 | promoter,gene body | 5.65e-01 | 7.15e-01 | -3.34e+00 | 8.39e-04 | 2.31e-03 | -1.50e-01 |
| LUSC | cg08124000 | chr11:3166520 | CGI:chr11:3164901-3165538 | promoter,gene body | 7.09e-01 | 8.93e-01 | -4.14e+00 | 3.40e-05 | 5.29e-04 | -1.85e-01 |
| LUSC | cg03361664 | chr11:3166530 | CGI:chr11:3164901-3165538 | promoter,gene body | 6.94e-01 | 8.83e-01 | -4.28e+00 | 1.86e-05 | 5.26e-04 | -1.88e-01 |
| LUSC | cg18897335 | chr11:3166560 | CGI:chr11:3164901-3165538 | promoter,gene body | 7.13e-01 | 8.97e-01 | -4.15e+00 | 3.33e-05 | 5.29e-04 | -1.84e-01 |
| LUSC | cg04976753 | chr11:3166691 | CGI:chr11:3164901-3165538 | promoter,exon,gene body | 8.19e-01 | 9.28e-01 | -3.01e+00 | 2.57e-03 | 5.00e-03 | -1.09e-01 |
| LUSC | cg19563452 | chr11:3166709 | CGI:chr11:3164901-3165538 | promoter,exon,gene body | 7.30e-01 | 8.67e-01 | -4.09e+00 | 4.34e-05 | 5.42e-04 | -1.36e-01 |
| LUSC | cg09330834 | chr11:3166786 | CGI:chr11:3164901-3165538 | promoter | 6.68e-01 | 8.97e-01 | -4.31e+00 | 1.60e-05 | 5.26e-04 | -2.29e-01 |
| LUSC | cg26391219 | chr11:3167977 | CGI:chr11:3164901-3165538 | promoter | 5.24e-01 | 6.34e-01 | -2.25e+00 | 2.44e-02 | 2.79e-02 | -1.10e-01 |
| BLCA | cg25487804 | chr11:3166281 | CGI:chr11:3164901-3165538 | promoter,gene body | 7.95e-01 | 9.07e-01 | -2.01e+00 | 4.48e-02 | 4.59e-02 | -1.12e-01 |
| BLCA | cg03857384 | chr11:3166547 | CGI:chr11:3164901-3165538 | promoter,gene body | 7.16e-01 | 9.44e-01 | -4.00e+00 | 6.26e-05 | 2.88e-04 | -2.28e-01 |
| BLCA | cg15718663 | chr11:3166554 | CGI:chr11:3164901-3165538 | promoter,gene body | 7.60e-01 | 9.54e-01 | -3.49e+00 | 4.85e-04 | 1.30e-03 | -1.94e-01 |
| BLCA | cg05982473 | chr11:3166573 | CGI:chr11:3164901-3165538 | promoter,gene body | 8.63e-01 | 9.85e-01 | -3.31e+00 | 9.46e-04 | 2.17e-03 | -1.22e-01 |
| BLCA | cg16712438 | chr11:3166167 | CGI:chr11:3164901-3165538 | promoter,gene body | 6.39e-01 | 8.28e-01 | -3.95e+00 | 7.91e-05 | 3.39e-04 | -1.89e-01 |
| BLCA | cg09729166 | chr11:3166359 | CGI:chr11:3164901-3165538 | promoter,gene body | 7.48e-01 | 8.62e-01 | -4.03e+00 | 5.69e-05 | 2.70e-04 | -1.14e-01 |
| BLCA | cg03617572 | chr11:3166401 | CGI:chr11:3164901-3165538 | promoter,gene body | 7.02e-01 | 8.37e-01 | -2.81e+00 | 4.94e-03 | 8.07e-03 | -1.35e-01 |
| BLCA | cg12348511 | chr11:3166448 | CGI:chr11:3164901-3165538 | promoter,gene body | 6.09e-01 | 8.09e-01 | -3.93e+00 | 8.42e-05 | 3.54e-04 | -2.00e-01 |
| BLCA | cg22353828 | chr11:3166474 | CGI:chr11:3164901-3165538 | promoter,gene body | 5.47e-01 | 6.95e-01 | -3.32e+00 | 8.85e-04 | 2.06e-03 | -1.48e-01 |
| BLCA | cg08124000 | chr11:3166520 | CGI:chr11:3164901-3165538 | promoter,gene body | 7.09e-01 | 8.83e-01 | -4.50e+00 | 6.85e-06 | 8.09e-05 | -1.74e-01 |
| BLCA | cg03361664 | chr11:3166530 | CGI:chr11:3164901-3165538 | promoter,gene body | 7.09e-01 | 8.63e-01 | -4.05e+00 | 5.09e-05 | 2.51e-04 | -1.54e-01 |
| BLCA | cg18897335 | chr11:3166560 | CGI:chr11:3164901-3165538 | promoter,gene body | 7.12e-01 | 8.73e-01 | -3.86e+00 | 1.15e-04 | 4.41e-04 | -1.61e-01 |
| BLCA | cg09330834 | chr11:3166786 | CGI:chr11:3164901-3165538 | promoter | 7.40e-01 | 8.76e-01 | -3.68e+00 | 2.38e-04 | 7.53e-04 | -1.36e-01 |
| LIHC | cg25487804 | chr11:3166281 | CGI:chr11:3164901-3165538 | promoter,gene body | 6.90e-01 | 9.14e-01 | -4.41e+00 | 1.03e-05 | 2.81e-05 | -2.25e-01 |
| LIHC | cg12491594 | chr11:3166296 | CGI:chr11:3164901-3165538 | promoter,gene body | 7.33e-01 | 9.75e-01 | -4.35e+00 | 1.34e-05 | 3.53e-05 | -2.42e-01 |
| LIHC | cg15718663 | chr11:3166554 | CGI:chr11:3164901-3165538 | promoter,gene body | 8.32e-01 | 9.68e-01 | -4.64e+00 | 3.44e-06 | 1.08e-05 | -1.36e-01 |
| LIHC | cg05982473 | chr11:3166573 | CGI:chr11:3164901-3165538 | promoter,gene body | 8.73e-01 | 9.87e-01 | -4.08e+00 | 4.60e-05 | 1.04e-04 | -1.14e-01 |
| LIHC | cg20345446 | chr11:3165574 | CGI:chr11:3164901-3165538 | UTR,promoter,exon,gene body | 3.18e-01 | 4.23e-01 | -3.35e+00 | 8.02e-04 | 1.30e-03 | -1.05e-01 |
| LIHC | cg06131936 | chr11:3166041 | CGI:chr11:3164901-3165538 | promoter,gene body | 3.33e-01 | 5.30e-01 | -4.77e+00 | 1.86e-06 | 6.34e-06 | -1.97e-01 |
| LIHC | cg01309081 | chr11:3166132 | CGI:chr11:3164901-3165538 | promoter,gene body | 5.26e-01 | 7.40e-01 | -4.28e+00 | 1.89e-05 | 4.78e-05 | -2.13e-01 |
| LIHC | cg16712438 | chr11:3166167 | CGI:chr11:3164901-3165538 | promoter,gene body | 5.72e-01 | 7.75e-01 | -4.39e+00 | 1.11e-05 | 3.00e-05 | -2.03e-01 |
| LIHC | cg19181160 | chr11:3166363 | CGI:chr11:3164901-3165538 | promoter,gene body | 7.59e-01 | 9.26e-01 | -4.45e+00 | 8.74e-06 | 2.43e-05 | -1.67e-01 |
| LIHC | cg03617572 | chr11:3166401 | CGI:chr11:3164901-3165538 | promoter,gene body | 5.89e-01 | 8.55e-01 | -5.11e+00 | 3.24e-07 | 1.42e-06 | -2.65e-01 |
| LIHC | cg12348511 | chr11:3166448 | CGI:chr11:3164901-3165538 | promoter,gene body | 4.68e-01 | 7.34e-01 | -5.40e+00 | 6.83e-08 | 3.83e-07 | -2.65e-01 |
| LIHC | cg22353828 | chr11:3166474 | CGI:chr11:3164901-3165538 | promoter,gene body | 4.26e-01 | 6.25e-01 | -5.16e+00 | 2.46e-07 | 1.12e-06 | -1.99e-01 |
| LIHC | cg12537619 | chr11:3166693 | CGI:chr11:3164901-3165538 | promoter,exon,gene body | 5.68e-01 | 6.94e-01 | -3.02e+00 | 2.51e-03 | 3.58e-03 | -1.25e-01 |
| CHOL | cg12970008 | chr11:3164865 | CGI:chr11:3164901-3165538 | promoter,gene body | 9.58e-02 | 2.71e-01 | -3.54e+00 | 4.02e-04 | 8.32e-03 | -1.75e-01 |
| CHOL | cg04092393 | chr11:3165699 | CGI:chr11:3164901-3165538 | UTR,promoter,exon,gene body | 1.14e-01 | 2.94e-01 | -3.46e+00 | 5.30e-04 | 8.63e-03 | -1.81e-01 |
| CHOL | cg12537619 | chr11:3166693 | CGI:chr11:3164901-3165538 | promoter,exon,gene body | 7.97e-01 | 6.95e-01 | 3.10e+00 | 1.96e-03 | 1.07e-02 | 1.02e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg26391219 | chr11:3167977 | CGI:chr11:3164901-3165538 | promoter | 6.08e-01 | 7.41e-01 | -9.73e+00 | 2.17e-22 | 1.45e-21 | -1.33e-01 |
| HNSC | cg12537619 | chr11:3166693 | CGI:chr11:3164901-3165538 | promoter,exon,gene body | 6.46e-01 | 5.25e-01 | 2.36e+00 | 1.81e-02 | 2.60e-02 | 1.21e-01 |
| HNSC | cg22766888 | chr11:3167336 | CGI:chr11:3164901-3165538 | promoter | 7.38e-01 | 8.40e-01 | -3.34e+00 | 8.48e-04 | 9.05e-03 | -1.02e-01 |
| LIHC | cg04092393 | chr11:3165699 | CGI:chr11:3164901-3165538 | UTR,promoter,exon,gene body | 2.81e-01 | 3.83e-01 | -2.14e+00 | 3.24e-02 | 3.54e-02 | -1.01e-01 |
Top |
Exon skipping events with PSI in TCGA for OSBPL5 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for OSBPL5 |
| ∗Please access CAeditome for RNA editing annotation. |
| Landscape of RNA editing events across multiple cancer types. |
 |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| LAML | OSBPL5-009 | chr11_3113422_- | 1.63e-01 | 2.57e-01 | -2.10e+00 | 3.59e-02 | 4.94e-02 | -9.46e-02 |
| LAML | OSBPL5-009 | chr11_3113543_- | 2.73e-01 | 4.00e-01 | -2.08e+00 | 3.72e-02 | 4.94e-02 | -1.27e-01 |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for OSBPL5 |
| TFs related to OSBPL5. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BRCA | PLAGL2 | OSBPL5 | 2.98e+00 | 2.63e-03 | 4.61e+00 | 9.89e-01 | Female-biased |
| BRCA | TFAP2B | OSBPL5 | 3.14e+00 | 7.82e-03 | 4.42e+00 | 9.81e-01 | Female-biased |
| OSBPL5 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for OSBPL5 |
| RBPs related to ES in OSBPL5. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| UVM | ENOX1 | exon_skip_68067 | 9.66e+00 | 9.88e-01 | 9.36e+00 | 9.83e-03 | Male-biased |
| THYM | SRSF9 | exon_skip_68062 | 6.59e+00 | 9.81e-01 | 6.10e+00 | 1.78e-03 | Male-biased |
| ESCA | PCBP2 | exon_skip_68068 | 8.68e+00 | 9.94e-01 | 7.88e+00 | 1.02e-03 | Male-biased |
| ESCA | RBM4 | exon_skip_68062 | 8.85e+00 | 8.32e-03 | 9.32e+00 | 9.89e-01 | Female-biased |
| GBM | PCBP2 | exon_skip_68068 | 8.32e+00 | 9.82e-01 | 7.99e+00 | 1.10e-02 | Male-biased |
| KICH | RBM4 | exon_skip_68062 | 9.16e+00 | 1.25e-02 | 9.46e+00 | 9.85e-01 | Female-biased |
| SKCM | SAMD4A | exon_skip_68074 | 7.31e+00 | 9.86e-01 | 6.80e+00 | 2.40e-03 | Male-biased |
| OSBPL5 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000021762 | AC093627.4,hsa-mir-32,OSBPL5 | Male-specific ceRNA | TCGA-BLCA |
| ENSG00000021762 | AL450326.1,hsa-mir-372,OSBPL5 | Male-specific ceRNA | TCGA-BLCA |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs11039700 | chr11:5929863:A:C | - | 0.126931604469591 | 0.0150718134317069 | LUSC | Female-baised eQTL |
| rs11529378 | chr11:5921890:G:C | - | 0.115238255471222 | 0.0404317716327172 | LUSC | Female-baised eQTL |
| rs74584920 | chr11:10977458:C:A | - | 0.0739787174892695 | 0.0278714866496011 | LUAD | Female-baised eQTL |
| rs118171251 | chr11:10965958:C:T | - | 0.0724628981456196 | 0.0399686076478526 | LUAD | Female-baised eQTL |
| rs10770150 | chr11:10961040:G:C | - | -0.0724628981456195 | 0.0399686076478526 | LUAD | Female-baised eQTL |
| rs584428 | chr11:10955697:A:G | - | 0.0723021250020674 | 0.0405603774276128 | LUAD | Female-baised eQTL |
| rs533972 | chr11:10956682:T:C | - | 0.0723021250020674 | 0.0405603774276128 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs4468345 | chr11:4487039:A:G | - | 0.358338476671809 | 0.00976211066338076 | PCPG | Male-baised eQTL |
| rs901282 | chr11:12201501:A:T | - | -0.067338632295196 | 0.0234658692126541 | COAD | Male-baised eQTL |
| rs1397597 | chr11:7932167:G:C | - | 0.0996405118325179 | 0.0438632445645433 | COAD | Male-baised eQTL |
| rs1858281 | chr11:7932297:A:G | - | 0.0996405118325179 | 0.0438632445645433 | COAD | Male-baised eQTL |
| rs9666900 | chr11:7934177:A:G | - | 0.0996405118325179 | 0.0438632445645433 | COAD | Male-baised eQTL |
| rs11022226 | chr11:12176867:C:G | - | 0.101944723506489 | 0.0456234482838227 | COAD | Male-baised eQTL |
| rs7131656 | chr11:12199106:G:T | - | -0.064611819049171 | 0.0480277836605744 | COAD | Male-baised eQTL |
| rs11026080 | chr11:3236413:C:A | - | -0.120285094052132 | 0.048418670110681 | COAD | Male-baised eQTL |
| rs12273630 | chr11:5343065:C:T | - | 0.12154718125391 | 0.0494910228659163 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000021762 |
| CpG Site: cg18591228 | |
| Position to Gene: gene | |
| Male Effect: -0.275563900172052 | |
| Female Effect: - | |
 | Gene ID: ENSG00000021762 |
| CpG Site: cg15964132 | |
| Position to Gene: gene | |
| Male Effect: -0.191168886939183 | |
| Female Effect: - | |
 | Gene ID: ENSG00000021762 |
| CpG Site: cg20511548 | |
| Position to Gene: gene | |
| Male Effect: -0.105555046630721 | |
| Female Effect: - | |
 | Gene ID: ENSG00000021762 |
| CpG Site: cg06849723 | |
| Position to Gene: gene | |
| Male Effect: -0.0620935950750795 | |
| Female Effect: - | |
 | Gene ID: ENSG00000021762 |
| CpG Site: cg00500359 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.333183051642011 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg18591228 | chr11:3154322 | gene | -0.275563900172052 | 6.1601842458369e-14 | -0.5306296325309182 | 5.397742060934972e-16 | KIRP |
| cg15964132 | chr11:3154406 | gene | -0.191168886939183 | 1.56861968112261e-09 | -0.46474942755064513 | 3.648517757012682e-12 | KIRP |
| cg20511548 | chr11:3157092 | gene | -0.105555046630721 | 1.52567710172575e-07 | -0.4146090759556463 | 9.411884760080582e-10 | KIRP |
| cg06849723 | chr11:3123525 | gene | -0.0620935950750795 | 3.84665388736801e-05 | -0.349368915477747 | 3.9667440907522237e-07 | KIRP |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg00500359 | chr11:3154395 | gene | -0.333183051642011 | 2.21471950596089e-08 | -0.4106611575032654 | 8.542662474973676e-12 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of OSBPL5 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000021762 | OSBPL5 | C0001973 | Alcoholic Intoxication, Chronic | 1 | PSYGENET |
